Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

Phase 1

Completed

• Conditions: Obesity

• Registration Number: NCT00331175
• Lead Sponsor: Pfizer

Brief Summary

The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2006-05-26
• Study First Submitted QC: 2006-05-26
• Study First Posted: 2006-05-29
• Study Start: 2006-07
• Status Verified: 2006-12
• Study Completion: 2006-12
• Last Update Submitted: 2006-12-14
• Last Update Posted: 2006-12-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

• BMI 27-35 kg/m2

Read More

Exclusion Criteria

• Women of childbearing potential

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Food intake

Secondary Outcome Measures

Name	Time	Method
Plasma biomarkers, safety, toleration

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 New Haven, Connecticut, United States